The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature

Current Cardiology Reviews

Volumn 13, Issue 3, 2017, Pages 209-216

  Diamantis, Evangelos ^a   Kyriakos, George ^a   Quiles Sanchez, Lourdes Victoria ^a   Farmaki, Paraskevi ^a   Troupis, Theodoros ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CAD prognosis; Coronary artery disease; CRP; Inflammation; Pleiotropic effect; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; COMPACTIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; MORBIDITY; MULTICENTER STUDY (TOPIC); MYOPATHY; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; BLOOD; INFLAMMATION; METABOLISM;

BIOMARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION;

EID: 85027271224     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X13666170426104611     Document Type: Review

References (71)

1. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4(12): 977-87.
2. Tousoulis D, Papageorgiou N, Briasoulis A, Antoniades C, Stefanadis C. The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule? Current Vasc Pharmacol 2010; 8(1): 114-21.
3. Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 2015; 6(3): 209-17.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-207.
6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504.
7. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3): 357-62.
8. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-35.
9. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57(14): 1535-45.
10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623-30.
11. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-92.
12. Corsonello A, Garasto S, Abbatecola AM, et al. Targeting inflammation to slow or delay functional decline: where are we? Bioger-ontology 2010; 11(5): 603-14.
13. Proksch E, Elias PM, Feingold KR. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in murine epidermis. Modulation of enzyme content and activation state by barrier requirements. J Clin Invest 1990; 85(3): 874-82.
14. Kapiotis S, Holzer G, Schaller G, et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol 2006; 26(11): 2541-6.
15. Barrientos S, Brem H, Stojadinovic O, Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen 2014; 22(5): 569-78.
16. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 2010; 159(6): 1294-303.
17. Singh P, Kohr D, Kaps M, Blaes F. Influence of statins on MHC class I expression. Ann N Y Acad Sci 2009; 1173: 746-51.
18. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPI-TER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther 2010; 4: 383-413.
19. Artom N, Montecucco F, Dallegri F, Pende A. Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. Eur J Clin Invest 2014; 44(11): 1122-34.
20. Banach M, Serban C, Sahebkar A, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med 2015; 13: 229.
21. Koskinas KC, Windecker S, Raber L. Regression of coronary atherosclerosis: Current evidence and future perspectives. Trends Cardiovasc Med 2016; 26(2): 150-61.
22. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14(1): 37-44.
23. van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veld-huisen DJ. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006; 71(3): 443-54.
24. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868-74.
25. Brili S, Tousoulis D, Antonopoulos AS, et al. Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. Heart 2012; 98(4): 325-9.
26. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1): 64-70.
27. Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis 2013; 12: 9.
28. Shibasaki M, Wang JG, Figueiredo JL, et al. Pitavastatin reduces inflammation in atherosclerotic plaques in apolipoprotein E-deficient mice with late stage renal disease. PLoS One 2015; 10(9): e0138047.
29. Shahbazian H, Atrian A, Yazdanpanah L, Lashkarara GR, Zafar Mohtashami A. Anti-inflammatory effect of simvastatin in hemodialysis patients. Jundishapur J Nat Pharm Prod 2015; 10(1): e17962.
30. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21(1): 115-21.
31. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43(3): 471-8.
32. Macin SM, Perna ER, Farias EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 2005; 149(3): 451-7.
33. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108(13): 1560-6.
34. Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17(12 Suppl 3): S231-5.
35. Krane V, Winkler K, Drechsler C, et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008; 74(11): 1461-7.
36. Nakagomi A, Shibui T, Kohashi K, et al. Differential effects of atorvastatin and pitavastatin on inflammation, insulin resistance, and the carotid intima-media thickness in patients with dyslipidemia. J Atheroscler Thromb 2015; 22(11): 1158-71.
37. Khurana S, Gupta S, Bhalla H, Nandwani S, Gupta V. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J Pharmacol Pharmacother 2015; 6(3): 130-5.
38. Sena CM, Matafome P, Louro T, Nunes E, Seica RM. Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes. Physiol Res 2014; 63(2): 189-97.
39. Tousoulis D, Papageorgiou N, Androulakis E, et al. Diabetes melli-tus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013; 62(8): 667-76.
40. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013; 19(27): 4904-12.
41. Sattar N, Taskinen MR. Statins are diabetogenic--myth or reality? Atheroscler Suppl 2012; 13(1): 1-10.
42. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012; 172(2): 144-52.
43. Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl 2014; 15(1): 1-15.
44. Sonal Sekhar M, Unnikrishnan MK. South-Asian population has a higher likelihood for diabetes risk for statins regardless of potency. Med Hypotheses 2015; 84(3): 283-4.
45. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61(2): 148-52.
46. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15(5): 269-75.
47. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010; 11(5): 817-28.
48. Cho Y, Choe E, Lee YH, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism 2015; 64(4): 482-8.
49. Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 2015; 241(2): 409-18.
50. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735-42.
51. Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis 2011; 214(1): 151-7.
52. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7(6): 687-92.
53. Zhao X, Liu Y, Zhong Y, et al. Atorvastatin improves inflammatory response in atherosclerosis by upregulating the expression of GARP. Mediators Inflamm 2015; 2015: 841472.
54. Tousoulis D, Koniari K, Antoniades C, et al. Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. Int J Cardiol 2011; 149(1): 46-9.
55. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347(20): 1557-65.
56. Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21(7): 1165-71.
57. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J 2008; 84(993): 368-71.
58. Sposito AR, Aguiar Filho GB, Aarao AR, Sousa FT, Bertolami MC. Statins in acute coronary syndromes. Arquivos Brasileiros Cardiol 2011; 97(4): 350-6.
59. Liu M, Yu Y, Jiang H, et al. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulat-ing the HMGB1-RAGE axis. Acta Pharmacol Sin 2013; 34(6): 830-6.
60. Brinjikji W, Yong Hong D, Dai D, Schroeder DJ, Kallmes DF, Kadirvel R. Statins are not associated with short-term improved aneurysm healing in a rabbit model of unruptured aneurysms. J Neu-rointerv Surg 2017; 9(2): 200-3.
61. Melo AC, Valenca SS, Gitirana LB, et al. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol 2013; 17(1): 57-64.
62. Manitsopoulos N, Orfanos SE, Kotanidou A, et al. Inhibition of HMGCoA reductase by simvastatin protects mice from injurious mechanical ventilation. Respir Res 2015; 16: 24.
63. Ndrepepa G, Fusaro M, King L, et al. Statin pretreatment and presentation patterns in patients with coronary artery disease. Cardiol J 2013; 20(1): 52-8.
64. Leoncini M, Toso A, Maioli M, et al. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv 2013; 6(2): 169-79.
65. O'Brien EC, Simon DN, Roe MT, Wang TY, Peterson ED, Alexander KP. Statin treatment by low-density lipoprotein cholesterol levels in patients with Non-ST-segment elevation myocardial in-farction/unstable angina pectoris (from the CRUSADE Registry). Am J Cardiol 2015; 115(12): 1655-60.
66. Mytas D, Zairis M, Karanasos A, et al. Effect of statin pretreatment on the outcome of ST-segment elevation myocardial infarction in patients without prior history of coronary artery disease. Hellenic J Cardiol 2013; 54(6): 422-8.
67. Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. Atherosclerosis 2015; 239(2): 439-43.
68. Liu HL, Yang Y, Yang SL, et al. Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study. Clin Therap 2013; 35(3): 261-72.
69. Sun F, Yin Z, Shi Q, Zhao B, Wang S. Effect of short-term high-dose atorvastatin on systemic inflammatory response and myocardial ischemic injury in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Chin Med J 2014; 127(21): 3732-7.
70. Yang J, Liu C, Zhang L, et al. Intensive Atorvastatin therapy attenuates the inflammatory responses in monocytes of patients with unstable angina undergoing percutaneous coronary intervention via peroxisome proliferator-activated receptor gamma activation. Inflammation 2015; 38(4): 1415-23.
71. Li J, Chen H, Ren J, et al. Effects of statin on circulating microR-NAome and predicted function regulatory network in patients with unstable angina. BMC Med Genom 2015; 8: 12.